|
1
|
Linch D: Developments over the last 60
years in diffuse large B-cell lymphomas. Br J Haematol.
191:552–557. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Harrysson S, Eloranta S, Ekberg S, Enblad
G, Jerkeman M, Wahlin BE, Andersson PO and Smedby KE: Incidence of
relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including
CNS relapse in a population-based cohort of 4243 patients in
Sweden. Blood Cancer J. 11(9)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zahid MF, Khan N, Hashmi SK, Kizilbash SH
and Barta SK: Central nervous system prophylaxis in diffuse large
B-cell lymphoma. Eur J Haematol. 97:108–120. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Haioun C, Besson C, Lepage E, Thieblemont
C, Simon D, Rose C, Tilly H, Sonet A, Lederlin P, Attal M, et al:
Incidence and risk factors of central nervous system relapse in
histologically aggressive non-Hodgkin's lymphoma uniformly treated
and receiving intrathecal central nervous system prophylaxis: A
GELA study on 974 patients. Groupe d'Etudes des Lymphomes de
l'Adulte. Ann Oncol. 11:685–690. 2000.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tilly H, Vitolo U, Walewski J, da Silva
MG, Shpilberg O, André M, Pfreundschuh M and Dreyling M: ESMO
Guidelines Working Group. Diffuse large B-cell lymphoma (DLBCL):
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23 (Suppl 7):vii78–82. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Feugier P, Virion JM, Tilly H, Haioun C,
Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, et
al: Incidence and risk factors for central nervous system
occurrence in elderly patients with diffuse large-B-cell lymphoma:
influence of rituximab. Ann Oncol. 15:129–133. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bernstein SH, Unger JM, Leblanc M,
Friedberg J, Miller TP and Fisher RI: Natural history of CNS
relapse in patients with aggressive non-Hodgkin's lymphoma: A
20-year follow-up analysis of SWOG 8516-the southwest oncology
group. J Clin Oncol. 27:114–119. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee KW, Yi J, Choi IS, Kim JH, Bang SM,
Kim DW, Im SA, Kim TY, Yoon SS, Lee JS, et al: Risk factors for
poor treatment outcome and central nervous system relapse in
diffuse large B-cell lymphoma with bone marrow involvement. Ann
Hematol. 88:829–838. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Villa D, Connors JM, Shenkier TN, Gascoyne
RD, Sehn LH and Savage KJ: Incidence and risk factors for central
nervous system relapse in patients with diffuse large B-cell
lymphoma: the impact of the addition of rituximab to CHOP
chemotherapy. Ann Oncol. 21:1046–1052. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chihara D, Oki Y, Matsuo K, Onoda H, Taji
H, Yamamoto K and Morishima Y: Incidence and risk factors for
central nervous system relapse in patients with diffuse large
B-cell lymphoma: Analyses with competing risk regression model.
Leuk Lymphoma. 52:2270–2275. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tai WM, Chung J, Tang PL, Koo YX, Hou X,
Tay KW, Quek R, Tao M and Lim ST: Central nervous system (CNS)
relapse in diffuse large B cell lymphoma (DLBCL): Pre- and
post-rituximab. Ann Hematol. 90:809–818. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
El-Galaly TC, Cheah CY, Bendtsen MD,
Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH,
Goldschmidt N, Shaulov A, et al: Treatment strategies, outcomes and
prognostic factors in 291 patients with secondary CNS involvement
by diffuse large B-cell lymphoma. Eur J Cancer. 93:57–68.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Susanibar-Adaniya S and Barta SK: Update
on diffuse large B cell lymphoma: A review of current data and
potential applications on risk stratification and management. Am J
Hematol. 96:617–629. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cheah CY, Herbert KE, O'Rourke K, Kennedy
GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS,
et al: A multicentre retrospective comparison of central nervous
system prophylaxis strategies among patients with high-risk diffuse
large B-cell lymphoma. Br J Cancer. 111:1072–1079. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Klanova M, Sehn LH, Bence-Bruckler I,
Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q,
et al: Integration of cell of origin into the clinical CNS
international prognostic index improves CNS relapse prediction in
DLBCL. Blood. 133:919–926. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kansara R: Central nervous system
prophylaxis strategies in diffuse large B cell lymphoma. Curr Treat
Options Oncol. 19(52)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gleeson M, Counsell N, Cunningham D,
Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A,
Smith P, et al: Central nervous system relapse of diffuse large
B-cell lymphoma in the rituximab era: Results of the UK NCRI
R-CHOP-14 vs. 21 trial. Ann Oncol. 28:2511–2516. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abramson JS, Hellmann M, Barnes JA,
Hammerman P, Toomey C, Takvorian T, Muzikansky A and Hochberg EP:
Intravenous methotrexate as central nervous system (CNS)
prophylaxis is associated with a low risk of CNS recurrence in
high-risk patients with diffuse large B-cell lymphoma. Cancer.
116:4283–4290. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yhim HY, Yoon DH, Kim SJ, Yang DH, Eom HS,
Kim KH, Park Y, Kim JS, Kim HJ, Suh C, et al: First-line treatment
for primary breast diffuse large B-cell lymphoma using
immunochemotherapy and central nervous system prophylaxis: A
multicenter phase 2 trial. Cancers (Basel). 12(2192)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Garwood MJ, Hawkes EA, Churilov L and
Chong G: Patient selection and tolerability of high-dose
methotrexate as central nervous system prophylaxis in diffuse large
B-cell lymphoma. Cancer Chemother Pharmacol. 85:133–140.
2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC, Vandenbroucke JP and STROBE Initiative: The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. J Clin Epidemiol. 61:344–349.
2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lee K, Yoon DH, Hong JY, Kim S, Lee K,
Kang EH, Huh J, Park CS, Lee SW and Suh C: Systemic HD-MTX for CNS
prophylaxis in high-risk DLBCL patients: A prospectively collected,
single-center cohort analysis. Int J Hematol. 110:86–94.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kuitunen H, Kaprio E, Karihtala P,
Makkonen V, Kauppila S, Haapasaari KM, Kuusisto M, Jantunen E,
Turpeenniemi-Hujanen T and Kuittinen O: Impact of central nervous
system (CNS) prophylaxis on the incidence of CNS relapse in
patients with high-risk diffuse large B cell/follicular grade 3B
lymphoma. Ann Hematol. 99:1823–1831. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wilson MR, Eyre TA, Martinez-Calle N,
Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J,
Mula Kh A, et al: Timing of high-dose methotrexate CNS prophylaxis
in DLBCL: An analysis of toxicity and impact on R-CHOP delivery.
Blood Adv. 4:3586–3593. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Eyre TA, Savage KJ, Cheah CY, El-Galaly
TC, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, et
al: CNS prophylaxis for diffuse large B-cell lymphoma. Lancet
Oncol. 23:e416–e426. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bobillo S, Joffe E, Sermer D, Mondello P,
Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, et
al: Prophylaxis with intrathecal or high-dose methotrexate in
diffuse large B-cell lymphoma and high risk of CNS relapse. Blood
Cancer J. 11(113)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Glantz MJ, Cole BF, Recht L, Akerley W,
Mills P, Saris S, Hochberg F, Calabresi P and Egorin MJ: High-dose
intravenous methotrexate for patients with nonleukemic
leptomeningeal cancer: Is intrathecal chemotherapy necessary? J
Clin Oncol. 16:1561–1567. 1998.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vitolo U, Chiappella A, Ferreri AJ,
Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H,
Lopez-Guillermo A, et al: First-line treatment for primary
testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS
prophylaxis, and contralateral testis irradiation: Final results of
an international phase II trial. J Clin Oncol. 29:2766–2772.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Eyre TA, Kirkwood AA, Wolf J, Hildyard C,
Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R,
et al: Stand-alone intrathecal central nervous system (CNS)
prophylaxis provide unclear benefit in reducing CNS relapse risk in
elderly DLBCL patients treated with R-CHOP and is associated
increased infection-related toxicity. Br J Haematol. 187:185–194.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nazir A, Fawad Siddique N and Hameed A:
CNS relapse of diffuse large B cell lymphoma A single centre
experience. Pak J Med Sci. 33:1454–1458. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Holte H, Leppä S, Björkholm M, Fluge O,
Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML,
Erlanson M, Kolstad A, et al: Dose-densified chemoimmunotherapy
followed by systemic central nervous system prophylaxis for younger
high-risk diffuse large B-cell/follicular grade 3 lymphoma
patients: results of a phase II Nordic lymphoma group study. Ann
Oncol. 24:1385–1392. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Siegal T and Goldschmidt N: CNS
prophylaxis in diffuse large B-cell lymphoma: If, when, how and for
whom? Blood Rev. 26:97–106. 2012.PubMed/NCBI View Article : Google Scholar
|
